FDA Peptide Review 2026, Canada

Research-use notice: This article is research and educational information only. It is not legal or medical advice. No dosing, administration or human-use guidance is provided. BlueNexLabs research-use-only products are not intended for human or veterinary use.

Publication status: Prepared for the BlueNexLabs Research Knowledge Centre. Status checked September 14, 2026. Regulatory and litigation developments may change; verify current primary sources before relying on this summary.

What the PCAC votes mean—and do not mean—plus Health Canada requirements and Eli Lilly’s 2025–2026 litigation involving tirzepatide and investigational retatrutide.

The key point

The FDA did not approve BPC-157, KPV, TB-500, MOTS-c, Semax or Epitalon in July 2026. The committee made non-binding recommendations about possible U.S. Section 503A compounding eligibility. The votes did not authorize retail peptide sales, validate online research products or change Canadian law.

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) met on July 23–24, 2026 to consider whether specified free-base and acetate forms of seven peptide families should eventually appear on the U.S. Section 503A Bulk Drug Substances List. Final FDA action would require a separate agency process, including formal rulemaking. The committee itself does not approve drugs or determine Canadian authorization.

Seven peptide families were considered:

• Recommended by PCAC: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax.

• Not recommended by PCAC: Emideltide, commonly called DSIP.

• FDA staff position: FDA reviewers recommended against listing the free-base and acetate forms of all seven.

• Immediate legal result: no FDA approval and no automatic change to the final 503A Bulks List.

What the FDA Committee Actually Reviewed

Section 503A describes conditions under which qualifying patient-specific pharmacy compounding may receive exemptions from selected requirements of the U.S. Federal Food, Drug, and Cosmetic Act. For a bulk drug substance that is not already a component of an FDA-approved drug and does not have an applicable USP or National Formulary monograph, placement on the 503A Bulks List can be an important part of the statutory pathway.

FDA’s evaluation considered four broad areas:

• Physical and chemical characterization of the substance.

• Safety issues associated with use in compounding.

• Available evidence of effectiveness or lack of effectiveness.

• Historical use in compounded drug products.

This is a compounding-policy assessment—not the full evidentiary review used to approve a finished drug through a New Drug Application or Biologics License Application.

July 2026 Results at a Glance

Source note: FDA agenda and briefing packages are primary materials. Vote tallies were reported from the meeting webcast and contemporaneous trackers because final FDA minutes were not available in the reviewed materials at the status-check date.

The Seven Peptide Reviews

BPC-157

FDA reviewed BPC-157 free base and acetate in relation to ulcerative colitis. Staff found gaps in substance characterization, limited human effectiveness evidence and unresolved questions involving aggregation, impurities and immunogenicity. FDA also noted that the evidence did not support the wider oral, subcutaneous, nasal and transdermal uses promoted in some markets.

Committee outcome: PCAC recommended both forms by 8–6, with one abstention. The result did not establish BPC-157 as safe or effective, approve a route or dose, or authorize products sold by online suppliers.

KPV

KPV was considered for wound healing and inflammatory conditions. FDA’s record was predominantly mechanistic and preclinical. FDA reported finding no human administration or exposure data by any route, leaving clinical safety, effectiveness, historical use and immunogenicity unresolved.

Committee outcome: The committee recommended both forms 8–6–1. KPV did not become FDA-approved, and the vote did not itself place KPV on the final 503A list.

TB-500

FDA evaluated TB-500 as a defined seven-amino-acid fragment rather than assuming that evidence for full-length thymosin beta-4 applies to the fragment. Staff cited naming and characterization concerns, missing quality specifications, inadequate direct human evidence and unresolved injectable immunogenicity risk.

Committee outcome: The committee recommended both forms 8–6–1. The outcome concerns the nominated bulk substances; it does not validate every product sold online under the TB-500 name.

MOTS-c

MOTS-c was evaluated for obesity and osteoporosis. FDA found that the evidence relied heavily on cellular and animal models, with incomplete dose-response information, uncertain molecular targets and insufficient human evidence for the nominated uses.

Committee outcome: PCAC voted 7–5–2 in favour. MOTS-c remained investigational and unapproved; the committee result changed the advisory signal, not the underlying legal status.

Emideltide, or DSIP

Emideltide was evaluated for chronic insomnia, narcolepsy and opioid withdrawal. FDA found no effectiveness study using the nominated subcutaneous route. Older intravenous studies were small, inconsistent or methodologically limited, and chronic-use safety and immunogenicity questions remained unresolved.

Committee outcome: The committee rejected both forms 6–7–1. Emideltide was the only peptide family on the agenda not to receive a favourable recommendation.

Epitalon

Epitalon was considered for insomnia—not general anti-aging or longevity claims. FDA found no clinical study establishing insomnia outcomes with the nominated subcutaneous product. Changes in melatonin-related measures did not establish a clinically meaningful sleep benefit, and human safety evidence for the proposed route was inadequate.

Committee outcome: PCAC recommended Epitalon 7–4–1. The recommendation did not validate telomere, lifespan or broad anti-aging claims and did not create an FDA-approved Epitalon medicine.

Semax

Semax was reviewed for cerebral ischemia, migraine and trigeminal neuralgia. FDA found limited and methodologically weak clinical references, including small studies with incomplete endpoint reporting, along with unresolved quality and injectable immunogenicity concerns.

Committee outcome: The committee recommended Semax 8–5–1. Semax therefore received a favourable advisory recommendation, but no FDA-approved indication, formulation or final 503A listing resulted from the meeting.

Advisory Recommendation, Compounding Eligibility and FDA Approval Are Different

A favourable PCAC vote means that an advisory panel recommended that FDA consider adding a defined bulk substance to the 503A list. FDA may accept, narrow, delay or reject that advice. If FDA proceeds, the agency must complete the applicable process before the regulation changes.

Even final 503A listing would not mean:

• The peptide is FDA-approved;

• FDA approved a specific indication, dose or route;

• Every compounded preparation is equivalent;

• FDA pre-reviewed each compounded product for safety, effectiveness or manufacturing quality;

• Online RUO products became lawful medicines.

Plain-language distinction: PCAC gives advice. FDA makes final regulatory decisions. Drug approval, compounding eligibility, research-material status and Canadian market authorization are separate legal questions.

Why the FDA Vote Does Not Determine Canadian Legality

FDA decisions apply in the United States. Health Canada independently determines whether a drug may be sold or advertised in Canada. Health Canada has stated that unauthorized injectable peptide products can pose serious risks and that authorized prescription products carry an eight-digit Drug Identification Number that can be checked in the Drug Product Database.

On April 9, 2026, Health Canada named examples including BPC-157, Epitalon, KPV, MOTS-c, TB-500 and retatrutide in an advisory concerning unauthorized injectable peptides. Health Canada stated that wording such as “For Research Use Only – Not for Human Consumption” does not, by itself, make a product legal or exempt from regulatory requirements.

Health Canada also announced in July 2026 that the Superior Court of Québec had granted a permanent injunction against Canlab Research and its representatives. According to the regulator, the order prohibited specified activities involving unauthorized injectable peptides, including advertising through websites and social media accessible from Canadian IP addresses.

Canadian advertising rules are separate from U.S. compounding rules. Health Canada describes advertising broadly and assesses the overall context, including claims, links, audience, sponsorship, scientific balance and commercial presentation. Educational wording can still be viewed as promotional where the surrounding content promotes an unauthorized product for human use.

For a fuller Canadian research-use overview, see Are Peptides Legal in Canada?.

Eli Lilly’s 2025–2026 Peptide Litigation

The FDA and Health Canada are government regulators. Eli Lilly’s lawsuits are private civil actions. They may overlap with regulatory concerns, but they use different legal theories and seek different remedies. The descriptions below distinguish allegations from judicial findings.

The 2025 Compounded-Tirzepatide Cases

In 2025, Eli Lilly brought civil actions involving telehealth sellers and compounders, including Aios, Inc. doing business as Fella Health and Delilah; Willow Health Services, Inc.; Adonis Health, Inc., associated with Henry Meds; Mochi Health-related entities; Strive Pharmacy; and Empower Pharmacy-related entities. The reported themes included allegedly misleading comparisons between compounded tirzepatide and Lilly’s FDA-approved products, promotion of unapproved oral tirzepatide, personalized-formulation claims and use of Lilly clinical data to market materially different products.

Fella Health and Delilah

Lilly filed against Aios, Inc. and related medical entities in the Northern District of California, Case No. 25-cv-03535-HSG. Lilly alleged false or misleading oral-tirzepatide effectiveness claims, use of injectable-tirzepatide study results to market compounded or oral products and prescription changes portrayed as personalized care. On March 26, 2026, the court granted the dismissal motion in part and denied it in part. The court dismissed Lilly’s corporate-practice-of-medicine theory for inadequate standing but allowed narrowed unfair-competition, false-advertising and conspiracy theories to proceed. This was a procedural pleading decision, not a final finding that all allegations were true.

Willow Health Services

Lilly’s case against Willow Health Services was filed in the Central District of California, Case No. 2:25-cv-03570-AB-MAR. Lilly alleged that Willow marketed injectable and oral compounded tirzepatide as extensively tested, science-backed and personalized despite the absence of FDA approval or clinical trials for Willow’s versions. On February 3, 2026, the court dismissed Lilly’s amended complaint with prejudice, holding that Lilly had not adequately pleaded proximate causation under the Lanham Act because the intervening physician-prescribing decision disrupted the alleged connection between advertising and lost sales. The ruling was not a regulatory endorsement of compounded tirzepatide.

Adonis Health and Henry Meds

In Eli Lilly and Company v. Adonis Health, Inc., Case No. 4:25-cv-03536, the Northern District of California issued a September 24, 2025 order granting the dismissal motion in part and denying it in part, with leave to amend. The dispute involved advertising and sale of compounded tirzepatide, including alleged representations concerning equivalence, efficacy and regulatory status. For other identified 2025 matters, complete current dockets and final outcomes were not available in the reviewed record. Their allegations should not be presented as adjudicated facts.

The 2026 Retatrutide “Research Use Only” Cases

In August 2026, Lilly filed a second group of cases targeting businesses allegedly selling products purporting to contain retatrutide, which remained investigational and unapproved at the status-check date.

• Astra LLC dba Astra Peptides — W.D. Tex., Case No. 5:26-cv-5147; complaint dated August 12, 2026.

• Aesthetic Envy LLC dba Legendary Peptides — N.D. Ind., Case No. 1:26-cv-00375-HAB-SLC.

• Striker Pharmacy LLC — Western District of Texas.

• 1st Optimal LLC dba Texas Peptides — Western District of Texas.

• Lone Star Peptide LLC — District of Colorado.

These were allegations in newly filed complaints. No final merits judgments were located in the record reviewed for this article.

The Astra complaint illustrates Lilly’s theory. Lilly alleged that “research use only” was a pretext because the website’s surrounding content discussed appetite, metabolic function and comparisons with GLP-1 medicines, while customer reviews allegedly described personal use and weight loss. Lilly asserted state-law unfair-competition and deceptive-practices claims and requested injunctive and monetary relief. Lilly further alleged that unapproved retatrutide sales could expose consumers to products with unknown composition, purity, potency or sterility; divert purchasers from Lilly’s approved products; free-ride on Lilly’s clinical investment; cause third-party product experiences to be attributed to Lilly or retatrutide; and damage the market or reputation of a future Lilly medicine if retatrutide is approved. These are Lilly’s allegations and stated rationales—not established judicial findings.

Why “Research Use Only” Did Not End the Dispute

The 2026 complaints did not focus only on words printed on a vial. Lilly pointed to the complete sales context, including product descriptions, claimed physiological effects, comparisons with approved medicines, social-media promotion, customer testimonials and alleged evidence of intended human use. The cases reinforce a broader compliance principle: RUO wording should not be assumed to neutralize contradictory marketing evidence.

Private Litigation Versus Government Enforcement

Practical Lessons for Canadian Research Suppliers and Publishers

• Treat RUO as a genuine operating model, not a footer. Product descriptions, categories, images, FAQs, testimonials, social media and customer support should be consistent with laboratory-research positioning.

• Do not describe a PCAC recommendation as FDA approval, legalization or immediate compounding authorization.

• Separate investigational status from approved status. Trial progress does not equal FDA or Health Canada authorization.

• Avoid efficacy, treatment, weight-loss, recovery, anti-aging, dosing or administration claims for unauthorized products.

• Avoid suggesting affiliation with Eli Lilly or equivalence to Mounjaro, Zepbound or any future Lilly retatrutide product.

• Do not treat a Certificate of Analysis as regulatory authorization. A COA may support analytical identity or purity for a tested sample; it does not establish clinical safety, efficacy, sterility, GMP compliance or market authorization. For how to interpret those reports, see How to Read a Peptide Certificate of Analysis.

• Keep educational and commercial content visibly separated. An enforcement article should not function as a product funnel.

• Review Canadian status independently. U.S. compounding developments do not determine Canadian sale, advertising or import requirements.

Frequently Asked Questions

Did the FDA approve BPC-157 in July 2026?

No. PCAC recommended specified BPC-157 bulk substances for possible 503A listing. The meeting did not produce FDA drug approval or final rulemaking.

Can U.S. pharmacies now compound the six recommended peptides?

Not because of the committee vote alone. A favourable advisory recommendation is not final FDA action.

Does the FDA vote make the peptides legal in Canada?

No. Health Canada applies Canadian law independently.

Does “Research Use Only” make a peptide legal in Canada?

No. Health Canada has stated that RUO wording does not, by itself, make an otherwise regulated product legal or exempt.

Is retatrutide approved?

No. At the status-check date, retatrutide remained an investigational Lilly compound, not an FDA- or Health Canada-authorized medicine.

Why is Eli Lilly suing peptide sellers?

Lilly has alleged consumer-safety risks, false or misleading advertising, unfair competition, misuse of clinical evidence, diverted sales and harm to its brands or investigational pipeline. These are allegations unless admitted or adjudicated.

Further reading on BlueNexLabs

Readers looking for educational context can continue with the Research Knowledge Centre, the site Frequently Asked Questions, and the About BlueNexLabs page.

Primary Sources and Further Reading

• U.S. Food and Drug Administration, July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee, including agenda, webcast information and event materials. Docket No. FDA-2025-N-6895.

• FDA, PCAC briefing-document introduction for the July 23–24, 2026 meeting.

• FDA briefing packages for the nominated free-base and acetate forms: BPC-157, KPV, TB-500, MOTS-c, Emideltide, Epitalon and Semax.

• FDA, final agenda, questions for the committee, and July 23 and July 24 presentation decks.

• Health Canada, Think twice before injecting peptides bought online: unauthorized products can seriously harm you, originally published April 9, 2026.

• Health Canada, Health Canada obtains permanent injunction preventing Canlab Research’s illegal sale of injectable peptides in Canada, July 2026.

• Food and Drugs Act (Canada) and Health Canada’s Drug Product Database for authorized products and Drug Identification Numbers.

Litigation source note

Case names, numbers and procedural outcomes summarized above are drawn from publicly described federal civil dockets and contemporaneous reporting available at the September 14, 2026 status-check date. The 2025 compounded-tirzepatide matters include Eli Lilly and Company v. Aios, Inc. (N.D. Cal., Case No. 25-cv-03535-HSG); Eli Lilly and Company v. Willow Health Services, Inc. (C.D. Cal., Case No. 2:25-cv-03570-AB-MAR); and Eli Lilly and Company v. Adonis Health, Inc. (N.D. Cal., Case No. 4:25-cv-03536). The 2026 retatrutide group includes Astra LLC dba Astra Peptides (W.D. Tex., Case No. 5:26-cv-5147); Aesthetic Envy LLC dba Legendary Peptides (N.D. Ind., Case No. 1:26-cv-00375-HAB-SLC); Striker Pharmacy LLC (W.D. Tex.); 1st Optimal LLC dba Texas Peptides (W.D. Tex.); and Lone Star Peptide LLC (D. Colo.). Complete current dockets and later orders should be checked before any legal conclusion is drawn. Complaint allegations are not findings of fact.

Editorial Disclaimer

This guide is research and educational information only. It is not legal advice, medical advice, regulatory advice or a substitute for primary-source review. No dosing, administration, compounding or human-use guidance is provided. A Pharmacy Compounding Advisory Committee recommendation is not FDA approval, not final 503A listing and not Health Canada authorization. BlueNexLabs research-use-only products are not intended for human or veterinary use. Regulatory and litigation developments may change after the September 14, 2026 status check; readers should verify current FDA, Health Canada and court records.